Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OSUR's Cash to Debt is ranked higher than
93% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. OSUR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OSUR' s 10-Year Cash to Debt Range
Min: 0.4  Med: 9.74 Max: No Debt
Current: No Debt
Equity to Asset 0.88
OSUR's Equity to Asset is ranked higher than
91% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. OSUR: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
OSUR' s 10-Year Equity to Asset Range
Min: 0.67  Med: 0.84 Max: 0.94
Current: 0.88
0.67
0.94
Interest Coverage No Debt
OSUR's Interest Coverage is ranked higher than
90% of the 105 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.02 vs. OSUR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OSUR' s 10-Year Interest Coverage Range
Min: 13.49  Med: 10000.00 Max: 9999.99
Current: No Debt
13.49
9999.99
F-Score: 7
Z-Score: 7.62
M-Score: -2.63
WACC vs ROIC
2.28%
0.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.48
OSUR's Operating margin (%) is ranked lower than
63% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.42 vs. OSUR: 0.48 )
Ranked among companies with meaningful Operating margin (%) only.
OSUR' s 10-Year Operating margin (%) Range
Min: -400  Med: -11.89 Max: 10.92
Current: 0.48
-400
10.92
Net-margin (%) 1.03
OSUR's Net-margin (%) is ranked lower than
60% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. OSUR: 1.03 )
Ranked among companies with meaningful Net-margin (%) only.
OSUR' s 10-Year Net-margin (%) Range
Min: -637.93  Med: -11.06 Max: 39.57
Current: 1.03
-637.93
39.57
ROE (%) 0.71
OSUR's ROE (%) is ranked lower than
60% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.05 vs. OSUR: 0.71 )
Ranked among companies with meaningful ROE (%) only.
OSUR' s 10-Year ROE (%) Range
Min: -104.65  Med: -7.37 Max: 28.22
Current: 0.71
-104.65
28.22
ROA (%) 0.62
OSUR's ROA (%) is ranked lower than
59% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. OSUR: 0.62 )
Ranked among companies with meaningful ROA (%) only.
OSUR' s 10-Year ROA (%) Range
Min: -96.15  Med: -6.04 Max: 25.09
Current: 0.62
-96.15
25.09
ROC (Joel Greenblatt) (%) 3.47
OSUR's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.82 vs. OSUR: 3.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OSUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -210.79  Med: -27.22 Max: 69.66
Current: 3.47
-210.79
69.66
Revenue Growth (3Y)(%) 2.80
OSUR's Revenue Growth (3Y)(%) is ranked lower than
57% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. OSUR: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OSUR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.7  Med: 6.90 Max: 65.1
Current: 2.8
-2.7
65.1
EPS Growth (3Y)(%) -25.00
OSUR's EPS Growth (3Y)(%) is ranked lower than
85% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. OSUR: -25.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OSUR' s 10-Year EPS Growth (3Y)(%) Range
Min: -56.3  Med: -25.95 Max: 35.7
Current: -25
-56.3
35.7
» OSUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OSUR Guru Trades in Q2 2014

Paul Tudor Jones 16,570 sh (New)
Jim Simons 436,679 sh (+86.77%)
Chuck Royce 680,821 sh (+29.68%)
Louis Moore Bacon 100,000 sh (unchged)
PRIMECAP Management 2,025,400 sh (-6.39%)
» More
Q3 2014

OSUR Guru Trades in Q3 2014

Jim Simons 536,503 sh (+22.86%)
Chuck Royce 686,321 sh (+0.81%)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 2,022,900 sh (-0.12%)
» More
Q4 2014

OSUR Guru Trades in Q4 2014

Paul Tudor Jones 38,691 sh (New)
PRIMECAP Management 2,022,900 sh (unchged)
Jim Simons 476,803 sh (-11.13%)
Chuck Royce 607,221 sh (-11.53%)
» More
Q1 2015

OSUR Guru Trades in Q1 2015

Paul Tudor Jones 100,730 sh (+160.34%)
Jim Simons 869,800 sh (+82.42%)
Chuck Royce 668,721 sh (+10.13%)
PRIMECAP Management 2,020,900 sh (-0.10%)
» More
» Details

Insider Trades

Latest Guru Trades with OSUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 380.76
OSUR's P/E(ttm) is ranked lower than
96% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.20 vs. OSUR: 380.76 )
Ranked among companies with meaningful P/E(ttm) only.
OSUR' s 10-Year P/E(ttm) Range
Min: 10.98  Med: 97.31 Max: 605
Current: 380.76
10.98
605
Forward P/E 99.01
OSUR's Forward P/E is ranked lower than
93% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.03 vs. OSUR: 99.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 494.00
OSUR's PE(NRI) is ranked lower than
97% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.60 vs. OSUR: 494.00 )
Ranked among companies with meaningful PE(NRI) only.
OSUR' s 10-Year PE(NRI) Range
Min: 10.96  Med: 99.75 Max: 847
Current: 494
10.96
847
P/B 1.81
OSUR's P/B is ranked higher than
69% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. OSUR: 1.81 )
Ranked among companies with meaningful P/B only.
OSUR' s 10-Year P/B Range
Min: 0.94  Med: 2.79 Max: 6.43
Current: 1.81
0.94
6.43
P/S 2.55
OSUR's P/S is ranked higher than
54% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. OSUR: 2.55 )
Ranked among companies with meaningful P/S only.
OSUR' s 10-Year P/S Range
Min: 1.53  Med: 4.41 Max: 9.29
Current: 2.55
1.53
9.29
PFCF 49.50
OSUR's PFCF is ranked lower than
72% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.29 vs. OSUR: 49.50 )
Ranked among companies with meaningful PFCF only.
OSUR' s 10-Year PFCF Range
Min: 25.48  Med: 99.81 Max: 99999999.99
Current: 49.5
25.48
99999999.99
POCF 35.36
OSUR's POCF is ranked lower than
76% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.15 vs. OSUR: 35.36 )
Ranked among companies with meaningful POCF only.
OSUR' s 10-Year POCF Range
Min: 20.45  Med: 42.67 Max: 94.11
Current: 35.36
20.45
94.11
EV-to-EBIT 179.21
OSUR's EV-to-EBIT is ranked lower than
97% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. OSUR: 179.21 )
Ranked among companies with meaningful EV-to-EBIT only.
OSUR' s 10-Year EV-to-EBIT Range
Min: -555.3  Med: -11.70 Max: 1731.8
Current: 179.21
-555.3
1731.8
Current Ratio 7.03
OSUR's Current Ratio is ranked higher than
91% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. OSUR: 7.03 )
Ranked among companies with meaningful Current Ratio only.
OSUR' s 10-Year Current Ratio Range
Min: 2.34  Med: 6.28 Max: 14.78
Current: 7.03
2.34
14.78
Quick Ratio 6.13
OSUR's Quick Ratio is ranked higher than
92% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. OSUR: 6.13 )
Ranked among companies with meaningful Quick Ratio only.
OSUR' s 10-Year Quick Ratio Range
Min: 1.87  Med: 5.68 Max: 14.11
Current: 6.13
1.87
14.11
Days Inventory 129.36
OSUR's Days Inventory is ranked higher than
50% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.36 vs. OSUR: 129.36 )
Ranked among companies with meaningful Days Inventory only.
OSUR' s 10-Year Days Inventory Range
Min: 49.25  Med: 109.46 Max: 296.56
Current: 129.36
49.25
296.56
Days Sales Outstanding 54.30
OSUR's Days Sales Outstanding is ranked higher than
65% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. OSUR: 54.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
OSUR' s 10-Year Days Sales Outstanding Range
Min: 38.83  Med: 59.50 Max: 84.73
Current: 54.3
38.83
84.73

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.12
OSUR's Price/Net Cash is ranked higher than
82% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.22 vs. OSUR: 4.12 )
Ranked among companies with meaningful Price/Net Cash only.
OSUR' s 10-Year Price/Net Cash Range
Min: 1.89  Med: 6.86 Max: 101.25
Current: 4.12
1.89
101.25
Price/Net Current Asset Value 2.74
OSUR's Price/Net Current Asset Value is ranked higher than
85% of the 100 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.96 vs. OSUR: 2.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OSUR' s 10-Year Price/Net Current Asset Value Range
Min: 1.4  Med: 6.12 Max: 28.26
Current: 2.74
1.4
28.26
Price/Tangible Book 2.32
OSUR's Price/Tangible Book is ranked higher than
65% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. OSUR: 2.32 )
Ranked among companies with meaningful Price/Tangible Book only.
OSUR' s 10-Year Price/Tangible Book Range
Min: 1.11  Med: 5.67 Max: 19.45
Current: 2.32
1.11
19.45
Price/Projected FCF 2.61
OSUR's Price/Projected FCF is ranked lower than
67% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. OSUR: 2.61 )
Ranked among companies with meaningful Price/Projected FCF only.
OSUR' s 10-Year Price/Projected FCF Range
Min: 1.14  Med: 3.95 Max: 34.63
Current: 2.61
1.14
34.63
Price/Median PS Value 0.58
OSUR's Price/Median PS Value is ranked higher than
90% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.27 vs. OSUR: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
OSUR' s 10-Year Price/Median PS Value Range
Min: 0.37  Med: 1.38 Max: 21.04
Current: 0.58
0.37
21.04
Price/Graham Number 5.04
OSUR's Price/Graham Number is ranked lower than
80% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. OSUR: 5.04 )
Ranked among companies with meaningful Price/Graham Number only.
OSUR' s 10-Year Price/Graham Number Range
Min: 1.4  Med: 4.03 Max: 19.69
Current: 5.04
1.4
19.69
Earnings Yield (Greenblatt) (%) 0.60
OSUR's Earnings Yield (Greenblatt) (%) is ranked lower than
63% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. OSUR: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OSUR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 1.25 Max: 3.4
Current: 0.6
0.1
3.4
Forward Rate of Return (Yacktman) (%) 36.69
OSUR's Forward Rate of Return (Yacktman) (%) is ranked higher than
93% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.94 vs. OSUR: 36.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OSUR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -84.8  Med: -0.05 Max: 60.4
Current: 36.69
-84.8
60.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:EP3.Germany,
OraSure Technologies Inc was formed in May 5, 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. and Epitope, Inc. and changing the state of incorporation of Epitope from Oregon to Delaware. The Company is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests that are performed at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. One of its diagnostic products, the OraQuick In-Home HIV Test got approved by the U.S. FDA for sale in the over-the-counter or consumer retail markets in the United States. Its in vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers. Through its subsidiary, DNAG, the Company manufacture and sell kits that are used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetics, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. The Company owns rights to trademarks and service marks that are necessary to conduct its business as currently operated. In the United States, it owns the OraSure, Intercept, OraQuick, OraQuick ADVANCE, Histofreezer, OraSure QuickFlu, Q.E.D., Oragene, ORAcollect, OMNIgene, Performagene, PrepIT, HEMAgene, and AUTO-LYTE. The competitors include medical diagnostic companies and specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions The Company is subject to other federal and state laws targeting fraud and abuse in the healthcare industry, including false claims laws, marketing conduct laws and laws constraining the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with physicians, hospitals, laboratories and other potential purchasers of medical devices.
» More Articles for OSUR

Headlines

Articles On GuruFocus.com
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 
Weekly CFO Sells Highlight: OSUR, DKS, P, MGAM, EROC Jul 09 2012 
Weekly CFO Sells Highlight: OSUR, BMC, EF, HAIN, GCI, VRSK, FIO May 21 2012 
Weekly CFO Sells Highlight: KKD, OSUR, LVLT, OVTI Jul 11 2011 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 09 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 06 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 05 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 06 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Positive Developments Around Ebola Aug 03 2015
Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test Aug 03 2015
6:01 am OraSure receives US FDA Emergency Use Authorization, for its OraQuick Ebola Rapid antigen... Aug 03 2015
Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test Aug 03 2015
Searching for Value in a Beaten Down Sector Jul 30 2015
OraSure Technologies Earnings Conference Call Invitation Jul 15 2015
OraSure Technologies Earnings Conference Call Invitation Jul 15 2015
OraSure Supports Rapid HIV Testing Initiatives in Recognition of National HIV Testing Day Jun 26 2015
OraSure Technologies to Present at the 2015 JMP Securities Life Sciences Conference Jun 16 2015
OraSure Technologies to Present at the 2015 JMP Securities Life Sciences Conference Jun 16 2015
Quick, cheap way to help stop deadly Ebola Jun 12 2015
OraSure Awarded $10.4 Million HHS Contract to Advance Rapid Ebola Test Clinical Development Jun 12 2015
OraSure Awarded $10.4 Million HHS Contract to Advance Rapid Ebola Test Clinical Development Jun 12 2015
Orasure Technologies to Present at the Jefferies 2015 Global Healthcare Conference May 22 2015
Orasure Technologies to Present at the Jefferies 2015 Global Healthcare Conference May 22 2015
OraSure Technologies Supports Rapid HCV Testing Initiatives Across the U.S. in Recognition of... May 19 2015
Today's Bell Ringer, May 19 May 19 2015
OraSure Technologies Supports Rapid HCV Testing Initiatives Across the U.S. in Recognition of... May 19 2015
Chronic Liver Disease Foundation and Walgreens to Launch Hepatitis C Testing Campaign May 19 2015
OraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK